Display options
Share it on
Full text links
Wiley Free PMC Article

Br J Pharmacol. 1989 Jul;97(3):709-16. doi: 10.1111/j.1476-5381.1989.tb12007.x.

Beta-adrenoceptor blocking effects of a selective beta 2-agonist, mabuterol, on the isolated, blood-perfused right atrium of the dog.

British journal of pharmacology

K Akahane, Y Furukawa, Y Ogiwara, M Haniuda, S Chiba

Affiliations

  1. Department of Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan.

PMID: 2474351 PMCID: PMC1854580 DOI: 10.1111/j.1476-5381.1989.tb12007.x
Free PMC Article

Abstract

1. Effects of (+/-)-1-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-tert.- butylamino-ethanol hydrochloride (mabuterol) on pacemaker activity and atrial contractility were investigated in the isolated and blood-perfused right atrium of the dog. 2. Mabuterol, injected into the sinus node artery of the isolated atrium, dose-dependently increased atrial rate and contractile force at doses of 0.01-10 nmol but the responses to over 10 nmol of mabuterol gradually decreased and mabuterol at higher doses induced biphasic cardiac responses, i.e., negative followed by positive cardiac responses. 3. The maximal increases in atrial rate and contractile force induced by mabuterol were 41.4% and 12.9%, respectively, of the maximal chronotropic and inotropic effects of isoprenaline. 4. Positive chronotropic and inotropic responses to mabuterol were dose-dependently inhibited by a selective beta 2-adrenoceptor antagonist, ICI 118,551. These responses were only slightly attenuated by atenolol. 5. Mabuterol (1-300 nmol) dose-dependently inhibited both dobutamine- and procaterol-induced positive chronotropic and inotropic responses. 6. These results indicate that mabuterol causes weak positive chronotropic and inotropic effects on the perfused canine right atrium by activating beta 2-adrenoceptors, and that higher concentrations non-selectively block both beta 1-and beta 2-adrenoceptors.

Similar articles

Cited by

References

  1. Nature. 1967 May 6;214(5088):597-8 - PubMed
  2. J Pharmacol Exp Ther. 1989 Mar;248(3):1276-82 - PubMed
  3. Naunyn Schmiedebergs Arch Pharmacol. 1975;289(3):315-25 - PubMed
  4. Jpn J Pharmacol. 1975 Aug;25(4):433-9 - PubMed
  5. Eur J Pharmacol. 1976 Dec;40(2):225-32 - PubMed
  6. J Pharmacol Exp Ther. 1977 Aug;202(2):326-36 - PubMed
  7. Naunyn Schmiedebergs Arch Pharmacol. 1977 Nov;300(2):101-5 - PubMed
  8. Mol Pharmacol. 1979 Jul;16(1):34-46 - PubMed
  9. J Pharm Pharmacol. 1979 Oct;31(10):686-90 - PubMed
  10. J Pharmacol Exp Ther. 1979 Dec;211(3):502-8 - PubMed
  11. J Pharmacol Exp Ther. 1980 Mar;212(3):503-8 - PubMed
  12. J Clin Invest. 1981 Jun;67(6):1703-11 - PubMed
  13. Circ Res. 1981 Aug;49(2):326-36 - PubMed
  14. J Cardiovasc Pharmacol. 1982 Jan-Feb;4(1):34-43 - PubMed
  15. J Cardiovasc Pharmacol. 1983 May-Jun;5(3):430-7 - PubMed
  16. Life Sci. 1983 Aug 1;33(5):467-73 - PubMed
  17. J Pharm Pharmacol. 1983 Dec;35(12):804-7 - PubMed
  18. J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1184-91 - PubMed
  19. J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1216-21 - PubMed
  20. Arzneimittelforschung. 1984;34(11A):1633-40 - PubMed
  21. Arzneimittelforschung. 1984;34(11A):1641-51 - PubMed
  22. Br J Pharmacol. 1985 Jan;84(1):227-35 - PubMed
  23. Br J Clin Pharmacol. 1985 May;19(5):619-30 - PubMed
  24. Naunyn Schmiedebergs Arch Pharmacol. 1985 Oct;331(1):60-70 - PubMed
  25. Naunyn Schmiedebergs Arch Pharmacol. 1986 Feb;332(2):142-7 - PubMed
  26. Jpn Heart J. 1986 Mar;27(2):223-32 - PubMed
  27. J Pharmacol Exp Ther. 1987 Jun;241(3):1041-7 - PubMed
  28. J Pharmacol Exp Ther. 1987 Jun;241(3):1048-64 - PubMed
  29. Naunyn Schmiedebergs Arch Pharmacol. 1987 Apr;335(4):403-11 - PubMed
  30. Cardiovasc Res. 1987 Feb;21(2):124-9 - PubMed
  31. Eur J Pharmacol. 1988 Nov 1;156(2):231-7 - PubMed
  32. Life Sci. 1967 Nov 1;6(21):2241-9 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources